Abstract: The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC.
Abstract: The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
Abstract: The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
Abstract: The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-1 which is represented by the following structural formula:
Abstract: The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
Abstract: The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
Abstract: The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a and its novel crystalline forms.
Abstract: The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
Abstract: The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification. wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures.
Type:
Grant
Filed:
August 22, 2016
Date of Patent:
September 7, 2021
Assignee:
Natco Pharma Limited
Inventors:
Durga Prasad Konakanchi, Buchappa Gongalla, Dharmendher Ragidi, Uma Naresh Babu Kotra, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
Abstract: Present invention relates to an improved process for the preparation of N—(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
Abstract: The present invention relates to novel intermediates of Eribulin and process for the preparation of the same. The process of the present invention is commercially viable and can be easily adopted for plant scale operations. The present invention relates to tetrahydrofuran compounds of formula I, X, XI, D and B.
Abstract: The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.
Abstract: The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
Abstract: The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.
Abstract: The present invention relates to an improved process for the preparation of Ibrutinib with high purity and high yields. The present process is cost effective and feasible in large scale production also. The present process avoids the mitsunobu reagent conditions also. The present Invention also relates to a process for the preparation of Crystalline form A and Crystalline form C of Ibrutinib.
Abstract: The present invention is related to an improved process for the preparation of Ceritinib with high yield and high purity. The present process is cost effective and feasible in large scale production also. The present invention also related to a stable amorphous form of Ceritinib and its preparation. The present invention also relates to a process for the preparation of Crystalline form A of Ceritinib.
Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
Abstract: The present invention relates to novel series of substituted 7-(morpholinyl)-2-(N-piperazinyl)-methyl thieno [2, 3-c] pyridines of the following structure of formula I. Where in R1, R2, R3 and R4 are defined.